Sayitoglu, Ece Canan http://orcid.org/0000-0002-7588-1338
Luca, Bogdan A.
Boss, Allison Paige http://orcid.org/0000-0001-5087-1291
Thomas, Benjamin Craig
Freeborn, Robert Arthur
Uyeda, Molly Javier http://orcid.org/0009-0002-7033-6637
Chen, Pauline Ping
Nakauchi, Yusuke http://orcid.org/0000-0002-6943-3811
Waichler, Colin
Lacayo, Norman http://orcid.org/0000-0003-4573-5118
Bacchetta, Rosa
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Gentles, Andrew J. http://orcid.org/0000-0002-0941-9858
Cepika, Alma-Martina http://orcid.org/0000-0003-2862-1901
Roncarolo, Maria Grazia
Article History
Received: 11 October 2023
Revised: 10 April 2024
Accepted: 11 April 2024
First Online: 9 May 2024
Competing interests
: MGR is a co-founder and has equity in Tr1X Inc.; serves on the Board of Directors of Atara Bio and Cosmo Pharmaceuticals and receives compensation for those activities. RM is on the Advisory Boards of Kodikaz Therapeutic Solutions, Orbital Therapeutics, Pheast Therapeutics, and 858 Therapeutics. RM is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics. However, none of these companies had input into the design, execution, interpretation, or publication of the work in this manuscript. All other authors declare no competing interests.